Alibaba Health Information Technology Ltd
Company Profile
Business description
Alibaba Health is of one of China's leading e-commerce platform specializing in healthcare-related products, including prescription drugs, OTC drugs, traditional Chinese medicine, health foods, and so on. The company operates both a third-party B2C service, or 3P, and its own direct-to-consumer business, or 1P, with its own inventory, which can both be accessed by Alibaba’s Tmall app and Alipay. The company also provides online consultation services in a separate app called Yilu or “Dr. Deer,” although its e-commerce businesses remain its core competency in the long-term. E-commerce accounted for 93% of revenue in fiscal year 2022. We estimate that AliHealth holds about 45% of market share in the industry in terms of GMV. AliHealth is 63.74% owned by its parent company, Alibaba Group.
Contact
Wangjing East Park
30th Floor, Greenland Center
Building 9, Zone 4
Chaoyang District
Beijing
CHNSector
Healthcare
Stock type
Defensive
Industry
Pharmaceutical Retailers
Fiscal Year End
31 March 2027
Employees
1,357
Stocks News & Analysis
stocks
Eli Lilly earnings: Mounjaro/Zepbound’s massive volume growth more than counters price pressure
stocks
OpenAI missed multiple revenue targets - here’s why it likely won’t IPO this year
stocks
Lower production and higher prices for ASX hydrocarbon play
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,950.80 | 25.10 | -0.28% |
| CAC 40 | 8,114.84 | 0.00 | 0.00% |
| DAX 40 | 24,292.38 | 337.82 | 1.41% |
| Dow JONES (US) | 49,652.14 | 790.33 | 1.62% |
| FTSE 100 | 10,378.82 | 165.71 | 1.62% |
| HKSE | 25,776.53 | 335.31 | -1.28% |
| NASDAQ | 24,892.31 | 219.07 | 0.89% |
| Nikkei 225 | 59,531.56 | 246.64 | 0.42% |
| NZX 50 Index | 12,907.92 | 4.61 | 0.04% |
| S&P 500 | 7,209.01 | 73.06 | 1.02% |
| S&P/ASX 200 | 8,730.80 | 20.20 | -0.23% |
| SSE Composite Index | 4,112.16 | 4.65 | 0.11% |